Kwangathi i-2022: I-Trametinib ingaba indinganiso entsha yokunakekelwa komdlavuza we-serous ovarian ophindaphindayo, osezingeni eliphansi (Mekinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy and anti-estrogens like tamoxifen by around 52 percent, adding six months of progression-free (period during which the cancer did not advance) survival for patients.
Kwabesifazane abangu-260 abanezimila ze-serous ovarian eziphindelelayo ababethole ukwelashwa ngamakhemikhali ngaphambilini, abacwaningi base-United States nase-United Kingdom baqhathanisa i-trametinib yomlomo kanye ngosuku neyodwa yezinhlobo ezinhlanu zokunakekelwa ezijwayelekile (okungaba imithi yamakhemikhali noma i-anti-estrogen). Uma kuqhathaniswa nokwelashwa okuvamile, abahlanganyeli be-trametinib babonise impendulo ephakeme ephindwe kane ekwelapheni ngemva kwezinyanga ezingu-15. I-Trametinib isebenze kahle kakhulu kunazo zonke ezinye izindlela zokwelapha, yehlisa ukuqhubekela phambili kwesifo izinyanga eziyi-13 (uma kuqhathaniswa nezinyanga eziyisikhombisa zokwelashwa okujwayelekile). Ukuqubuka kwesikhumba, i-anemia, umfutho wegazi ophakeme, isifo sohudo, nokukhathala ngezinye zemiphumela emibi engaba yingozi yokwelashwa kwe-trametinib.
Low-grade serous umdlavuza wesibeletho is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.
